A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.

Berenson J, Manges R, Badarinath S, Cartmell A, McIntyre K, Lyons R, Harb W, Mohamed H, Nourbakhsh A, Rifkin R Abstract Elotuzumab, an immunostimulatory SLAMF7-targeting monoclonal antibody, induces myeloma cell death with minimal effects on normal tissue. In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3-h infusion), READ MORE


CHAMPION-1: a phase 1/2 study of weekly carfilzomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma Running title (max 50 characters including spaces): Weekly carfilzomib and dexamethasone for RRMM James R. Berenson,1 Alan Cartmell,2 Alberto Bessudo,3 Roger M. Lyons,4 Wael Harb,5 Dimitrios Tzachanis,6 Richy Agajanian,7 Ralph Boccia,8 Morton Coleman,9 Robert A. Moss,10 Robert READ MORE

Biology of Human Tumors

Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma Eric Sanchez, Abigail Gillespie, George Tang, Morgan Ferros, Nika Manik Harutyunyan, Suzie Vardanyan, Jillian Gottlieb, Mingjie Li, Cathy S.Wang, Haiming Chen, and James R. Berenson Abstract Purpose: Reduced uninvolved immunoglobulin (Ig) levels are a hallmark of multiple myeloma. We previously showed that Bcell maturation READ MORE

Advances in the Management of Multiple Myeloma

James R Berenson, MD,abc Tanya M Spektor, PhD,c and James Wang, MDab aInstitute for Myeloma and Bone Cancer Research; bJames R Berenson, MD, Inc; and cOncotherapeutics, West Hollywood, California Correspondence: James R Berenson, MD; jberenson@imbcr.org. Disclosures: Dr Berenson is a consultant for and receives honoraria and research funding from Takeda, Amgen, Jansen, Celgene, and Bristol-Meyers-Squibb. READ MORE

Risk of Skin Cancer in Multiple Myeloma Patients

a retrospective cohort study Austin A. Robinson1, James Wang2, Suzie Vardanyan3, Erik K. Madden4, Frank Hebroni4, Kyle A. Udd2, Tanya M. Spektor5, Jason D. Nosrati3, Alex Z. Kitto3, Michael Zahab3, Simrin Cheema6, Darron H. Fors4, Adam Norberg4, Joseph Diehl4, Gabriel N. Waterman7, Regina A. Swift2, John Crowley8, James R. Berenson2,3,5. 1Yale University School of Medicine, READ MORE

Skechers Performance Los Angeles Marathon

FOR IMMEDIATE RELEASE Contact: Molly Biddiscombe (212) 796-9826 molly.biddiscombe@ketchum.com Jolene Abbott 310.318.3100 x 4839 jolenea@skechers.com SKECHERS PERFORMANCE BECOMES TITLE SPONSOR OF LOS ANGELES MARATHON Global Leader in Performance Footwear Signs Multi-Year Agreement Commencing with the 2016 Skechers Performance Los Angeles Marathon. LOS ANGELES, Calif. (August 27, 2015) – LA MARATHON LLC and Skechers Performance, which READ MORE


Raise awareness with a “Friend Raiser” party! As a small, nonprofit we do not have a large advertising budget and rely on donations. So the challenge, with our limited means, is how to make more people aware of our work. Recently, we came up with an interesting and enjoyable way to spread our message, and READ MORE

New Automobile Donation Program

Created To Benefit The Institute for Myeloma and Bone Cancer Research The Institute for Myeloma and Bone Cancer Research is proud to announce a new way to support the organization. We have established a program that accepts your unwanted automobiles as valuable donations! It’s easy and free to donate your vehicle. You can call 1-800-240-0160 READ MORE

Counterpoints: Do Patients With Multiple Myeloma Need Maintenance Treatment?

By Clinical Advances in Hematology & Oncology March 2015, Volume 13, Issue 3 Multiple myeloma is an incurable disease, and patients who respond to treatment eventually relapse—which makes long-term maintenance therapy an appealing option. But is a treatment with an unclear effect on overall survival worth the side effects and financial cost? In this month’s READ MORE